Daniel Brungs

1.4k citations

47 papers · 565 indexed · h-index 14

Impact in

Oncology top 10%
- Cancer Cells and Metastasis
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Surgical Treatments
- Colorectal Cancer Screening and Detection
Cancer Research top 10%
- Cancer Genomics and Diagnostics

Papers in ⓘ

Oncology 41
- Cancer Cells and Metastasis 9
- Cancer Immunotherapy and Biomarkers 9
- CAR-T cell therapy research 8
- Colorectal Cancer Screening and Detection 6
- Colorectal Cancer Surgical Treatments 5
Immunology 10
- Immunotherapy and Immune Responses 6

Co-authors: Morteza Aghmesheh (19 shared papers)Therese M. Becker (13 shared papers)Martin Carolan (9 shared papers)Marie Ranson (13 shared papers)Kara L. Vine (9 shared papers)Paul de Souza (9 shared papers)Richard J. Epstein (2 shared papers)Aimee R. Hayes (1 shared paper)
Journals: Journal of Clinical Oncology (8 papers)Cancers (4 papers)Annals of Oncology (3 papers)International Journal of Molecular Sciences (2 papers)PLoS ONE (2 papers)
Partner nations: Australia United States New Zealand

In The Last Decade

Daniel Brungs

41 papers receiving 562 citations

Peers

Countries citing papers authored by Daniel Brungs

Since Specialization

Citations

This map shows the geographic impact of Daniel Brungs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Brungs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Brungs more than expected).

Fields of papers citing papers by Daniel Brungs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Brungs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Brungs. The network helps show where Daniel Brungs may publish in the future.

Co-authors

The 25 scholars most cited alongside Daniel Brungs, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel Brungs Line = papers co-authored together Daniel Brungs links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 47 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Gastric cancer stem cells: evidence, potential markers, and clinical implications Journal of Gastroenterology ·Daniel Brungs, Morteza Aghmesheh, Kara L. Vine, Therese M. Becker, Martin Carolan, Marie Ranson	2015	106
2	Human TERT promoter mutations as a prognostic biomarker in glioma Journal of Cancer Research and Clinical Oncology ·Branka Powter, Sarah A. Jeffreys, Heena Sareen, Adam Cooper, Daniel Brungs, Joseph W. Po, Tara L. Roberts, Eng‐Siew Koh, Kieran F. Scott, Mila Sajinovic, Joey Yusof Vessey, Paul de Souza, Therese M. Becker	2021	43
3	The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis Oncotarget ·Daniel Brungs, Julia Chen, Morteza Aghmesheh, Kara L. Vine, Therese M. Becker, Martin Carolan, Marie Ranson	2017	43
4	Establishment of novel long-term cultures from EpCAM positive and negative circulating tumour cells from patients with metastatic gastroesophageal cancer Scientific Reports ·Daniel Brungs, Elahe Minaei, Ann‐Katrin Piper, Jay R. Perry, Ashleigh Splitt, Martin Carolan, Shantay Ryan, Xiao Wu, Stéphanie Corde, Moeava Tehei, Morteza Aghmesheh, Kara L. Vine, Therese M. Becker, Marie Ranson	2020	37
5	Sidedness is prognostic in locoregional colon cancer: an analysis of 9509 Australian patients BMC Cancer ·Daniel Brungs, Morteza Aghmesheh, Paul de Souza, Weng Ng, Wei Chua, Martin Carolan, Philip R. Clingan, Emma Healey, June Rose, Tameika Tubaro, Marie Ranson	2017	36
6	Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAFV600E-mutant metastatic colorectal carcinoma Current Oncology ·K. Connolly, Daniel Brungs, E. Szeto, Richard J. Epstein	2013	35
7	The Role of Liquid Biopsies in Detecting Molecular Tumor Biomarkers in Brain Cancer Patients Cancers ·Heena Sareen, Celine Garrett, David T. Lynch, Branka Powter, Daniel Brungs, Adam Cooper, Joseph W. Po, Eng‐Siew Koh, Joey Yusof Vessey, Simon McKechnie, Renata Bazina, Mark Sheridan, James van Gelder, Balsam Darwish, Mathias Jaeger, Tara L. Roberts, Paul de Souza, Therese M. Becker	2020	33
8	Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis PLoS ONE ·Aimee R. Hayes, Daniel Brungs, Nick Pavlakis	2018	20
9	Cryopreservation for delayed circulating tumor cell isolation is a valid strategy for prognostic association of circulating tumor cells in gastroesophageal cancer World Journal of Gastroenterology ·Daniel Brungs, David T. Lynch, Alison W. S. Luk, Elahe Minaei, Marie Ranson, Morteza Aghmesheh, Kara L. Vine, Martin Carolan, Mouhannad Jaber, Paul de Souza, Therese M. Becker	2018	19
10	Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis Prostate Cancer and Prostatic Diseases ·Daniel Brungs, J Chen, Philip Masson, Richard J. Epstein	2014	19
11	Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer Clinical Colorectal Cancer ·Daniel Brungs, Morteza Aghmesheh, Paul de Souza, Martin Carolan, Philip R. Clingan, June Rose, Marie Ranson	2018	19
12	Central Venous Catheter Thrombosis in Cancer: A Multi-Centre Retrospective Study Investigating Risk Factors and Contemporary Trends in Management Clinical Medicine Insights Oncology ·Lucy Haggstrom, Gurdeep Parmar, Daniel Brungs	2020	18
13	Comparison of peripheral blood mononuclear cell isolation techniques and the impact of cryopreservation on human lymphocytes expressing CD39 and CD73 Purinergic Signalling ·Ross J. Turner, Nicholas J. Geraghty, Jonathan G. Williams, Diane Ly, Daniel Brungs, Martin Carolan, Thomas V. Guy, Debbie Watson, Jeremiah de Leon, Ronald Sluyter	2020	17
14	Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status PLoS ONE ·Joseph W. Po, Yafeng Ma, Bavanthi Balakrishna, Daniel Brungs, Farhad Azimi, Paul de Souza, Therese M. Becker	2019	15
15	Expression of cancer stem cell markers is prognostic in metastatic gastroesophageal adenocarcinoma Pathology ·Daniel Brungs, Alistair Lochhead, Anita Iyer, Martin Illemann, Peter Colligan, Nicholas Hirst, Ashleigh Splitt, Winston Liauw, Kara L. Vine, Sarennya Pathmanandavel, Martin Carolan, Therese M. Becker, Morteza Aghmesheh, Marie Ranson	2019	10
16	Combination chemotherapy with NAB^®‐paclitaxel and capecitabine for patients with advanced biliary tract cancer (NAP‐CAPABIL Pilot Study) Asia-Pacific Journal of Clinical Oncology ·Rachel Woodford, Daniel Brungs, Carly Leighton, Peter Grimison, Katrin Marie Sjoquist, Therese M. Becker, Samuel Robinson, Val Gebski, Kate Wilson, Lorraine A. Chantrill, Morteza Aghmesheh	2021	8
17	Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures. Journal of Clinical Oncology ·Pasi A. Jänne, Mengzhao Wang, D. Ross Camidge, Paul Mitchell, Jian Fang, Weiqi Nian, Chao‐Hua Chiu, Jianying Zhou, Yanqiu Zhao, Wu‐Chou Su, Tsung‐Ying Yang, Viola W. Zhu, Michael Millward, Yun Fan, Wen‐Tsung Huang, Ying Cheng, Liyan Jiang, Daniel Brungs, Zheng Li, James Chih‐Hsin Yang	2022	8
18	High body mass index is associated with an increased overall survival in rectal cancer Journal of Gastrointestinal Oncology ·Karolina Juszczyk, Sharlyn Kang, Soni Putnis, Robert Winn, James Chen, Morteza Aghmesheh, Glaucia Fylyk, Daniel Brungs	2020	7
19	Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma Cancers ·Gary Tincknell, Ann‐Katrin Piper, Morteza Aghmesheh, Therese M. Becker, Kara L. Vine, Daniel Brungs, Marie Ranson	2021	7
20	1084P Cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma (mCSCC): Preliminary safety and efficacy results from a phase I clinical trial Annals of Oncology ·P. Clingan, Daniel Brungs, Rahul Ladwa, Andrew Mant, Margaret McGrath, Andrea Tazbirkova, P. Koralewski, Iwona Ługowska, Chaiyut Charoentum, Arunee Dechaphunkul, Virote Sriuranpong, James Oliviero, Dean Harris	2020	6

About Daniel Brungs

Daniel Brungs is a scholar working on Oncology, Immunology, Cancer Research, Biotechnology and Physiology, having authored 47 papers that have together received 565 indexed citations. Recurring topics across this work include Cancer Cells and Metastasis (9 papers), Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (8 papers), Immunotherapy and Immune Responses (6 papers), Nonmelanoma Skin Cancer Studies (6 papers), Colorectal Cancer Screening and Detection (6 papers), Colorectal Cancer Surgical Treatments (5 papers) and Lung Cancer Treatments and Mutations (5 papers). The work is most often cited by research in Oncology (322 citations), Cancer Research (175 citations), Genetics (53 citations), Pulmonary and Respiratory Medicine (151 citations) and Biotechnology (35 citations). Daniel Brungs has collaborated with scholars based in Australia, United States and New Zealand. Frequent co-authors include Morteza Aghmesheh, Therese M. Becker, Martin Carolan, Marie Ranson, Kara L. Vine, Paul de Souza, Richard J. Epstein, Aimee R. Hayes, Joseph W. Po and Nick Pavlakis. Their work appears in journals such as Journal of Clinical Oncology, Cancers, Annals of Oncology, International Journal of Molecular Sciences and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact